Strides Pharma Science Intrinsic Value
STAR • Healthcare
Current Stock Price
₹994.10
Primary Intrinsic Value
₹1217.92
Market Cap
₹9146 Cr
-7.6%
Downside
Median Value
₹918.26
Value Range
₹354 - ₹1218
Assessment
Trading Near Calculated Value
Safety Margin
-8.3%
STAR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1217.92 | ₹974.34 - ₹1461.50 | +22.5% | EPS: ₹55.36, Sector P/E: 22x |
| Book Value Method | asset | ₹562.39 | ₹506.15 - ₹618.63 | -43.4% | Book Value/Share: ₹281.20, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1085.22 | ₹976.70 - ₹1193.74 | +9.2% | Revenue/Share: ₹542.61, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1082.61 | ₹974.35 - ₹1190.87 | +8.9% | EBITDA: ₹996.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹918.30 | ₹734.64 - ₹1101.96 | -7.6% | CF Growth: 12.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹354.30 | ₹318.87 - ₹389.73 | -64.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹855.31 | ₹769.78 - ₹940.84 | -14.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹918.26 | ₹826.43 - ₹1010.09 | -7.6% | ROE: 20.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹562.39 | ₹506.15 - ₹618.63 | -43.4% | EPS: ₹55.36, BVPS: ₹281.20 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
STAR Intrinsic Value Analysis
What is the intrinsic value of STAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Strides Pharma Science (STAR) is ₹918.26 (median value). With the current market price of ₹994.10, this represents a -7.6% variance from our estimated fair value.
The valuation range spans from ₹354.30 to ₹1217.92, indicating ₹354.30 - ₹1217.92.
Is STAR undervalued or overvalued?
Based on our multi-method analysis, Strides Pharma Science (STAR) appears to be trading near calculated value by approximately 7.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.56 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 20.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.83x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Strides Pharma Science
Additional stock information and data for STAR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹684 Cr | ₹639 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹701 Cr | ₹626 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹44 Cr | ₹44 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-258 Cr | ₹-318 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹481 Cr | ₹220 Cr | Positive Free Cash Flow | 7/10 |